Status:
COMPLETED
Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Pretium Pty Ltd
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
45+ years
Phase:
NA
Brief Summary
The primary objective of the study is to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index of less than or equal to 0.9, in subjects wit...
Eligibility Criteria
Inclusion
- Males aged 45 years or above or females aged 55 years or above (age related CVD risk factor).
- At least two other risk factors for CVD: cigarette smoking, diabetes mellitus, hypertension, low HDL or high LDL cholesterol, strong family history of coronary heart disease, elevated waist circumference, Aboriginal and/or Torres Strait Islander.
- Willingness to participate in study and sufficient command of the English language to read and complete study questionnaire.
Exclusion
- Less than 2 risk factors for CVD (other than age), symptoms of PAD, coronary heart disease or coronary heart disease risk equivalents
- No lipid data collected in the last 12 months
- Serious or unstable medical or psychological conditions that, in the opinion of the Investigator, would compromise safety or successful participation in the study.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00928629
Start Date
June 1 2009
End Date
October 1 2009
Last Update
November 13 2009
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Edgecliff, New South Wales, Australia
2
Research Site
Hinchinbrook, New South Wales, Australia
3
Research Site
Kingsford, New South Wales, Australia
4
Research Site
Kingswood, New South Wales, Australia